Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Anavex Life Sciences Corp. (AVXL : NSDQ)
 
 • Company Description   
ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.

Number of Employees: 42

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.18 Daily Weekly Monthly
20 Day Moving Average: 950,464 shares
Shares Outstanding: 85.37 (millions)
Market Capitalization: $954.46 (millions)
Beta: 0.72
52 Week High: $14.44
52 Week Low: $4.93
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 36.01% 30.92%
12 Week 24.92% 5.07%
Year To Date 4.10% -2.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
630 5TH AVENUE 20TH FLOOR
-
NEW YORK,NY 10111
USA
ph: 844-689-3939
fax: -
ir@anavex.com http://www.anavex.com
 
 • General Corporate Information   
Officers
Christopher Missling - Chief Executive Officer;Director; President and Se
Jiong Ma - Chairman and Director
Sandra Boenisch - Principal Financial Officer and Treasurer
Athanasios Skarpelos - Director
Claus van der Velden - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 032797300
SIC: 2836
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 85.37
Most Recent Split Date: 10.00 (0.25:1)
Beta: 0.72
Market Capitalization: $954.46 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 9.57
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 7.14%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -40.93
12/31/24 - -37.50
ROA
06/30/25 - -
03/31/25 - -36.38
12/31/24 - -34.08
Current Ratio
06/30/25 - -
03/31/25 - 6.74
12/31/24 - 9.45
Quick Ratio
06/30/25 - -
03/31/25 - 6.74
12/31/24 - 9.45
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.17
12/31/24 - 1.31
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©